Clinical use of high mobility group box 1 and the receptor for advanced glycation end products in the prognosis and risk stratification of heart failure: A literature review

Canadian Journal of Physiology and Pharmacology

Volumn 95, Issue 3, 2016, Pages 253-259

  Marsh, Amanda M ^a   Nguyen, Austin Huy ^a   Parker, Taylor M ^a   Agrawal, Devendra K ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Heart failure; High mobility group box 1; HMGB1; Prognosis; RAGE; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; GELATINASE A; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; AGER PROTEIN, HUMAN; BIOLOGICAL MARKER; HMGB1 PROTEIN, HUMAN;

CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; HAPLOTYPE; HEART DEATH; HEART FAILURE; HUMAN; HYPERTENSION; INDEL MUTATION; INFLAMMATION; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SYSTEMATIC REVIEW; METABOLISM; PATHOPHYSIOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; UPREGULATION;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; BIOMARKERS; HEART FAILURE; HMGB1 PROTEIN; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 85014729193     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2016-0299     Document Type: Review

References (15)

1. Bangert, A., Andrassy, M., Müller, A.-M., Bockstahler, M., Fischer, A., Volz, C.H., et al. 2016. Critical role of RAGE and HMGB1 in inflammatory heart disease. Proc. Natl. Acad. Sci. U.S.A. 113(2): E155–E164. doi:10.1073/pnas.1522288113. PMID:26715748.
2. Boschetto, P., Campo, I., Stendardo, M., Casimirri, E., Tinelli, C., Gorrini, M., et al. 2013. Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. Eur. J. Clin. Invest. 43(6): 562–569. doi:10.1111/eci.12079. PMID: 23590548.
3. Cohen, C.R., Diel, V.B.N., La, Porta V.L., Rohde, L.E., Biolo, A., Clausell, N., and dos Santos, K.G. 2012. Association study of polymorphisms in the receptor for advanced glycation end-products (RAGE) gene with susceptibility and prognosis of heart failure. Gene, 510(1): 7–13. doi:10.1016/j.gene.2012.08.043. PMID: 22964273.
4. Gargiulo, P., Banfi, C., Ghilardi, S., Magrì, D., Giovannardi, M., Bonomi, A., et al. 2014. Surfactant-derived proteins as markers of alveolar membrane damage in heart failure. PLoS One, 9(12): e115030. doi:10.1371/journal.pone.0115030.
5. Goldin, A., Beckman, J.A., Schmidt, A.M., and Creager, M.A. 2006. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation, 114(6): 597–605. doi:10.1161/CIRCULATIONAHA.106.621854. PMID:16894049.
6. Koyama, Y., Takeishi, Y., Niizeki, T., Suzuki, S., Kitahara, T., Sasaki, T., and Kubota, I. 2008. Soluble receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J. Card. Failure, 14(2): 133–139. doi:10.1016/j.cardfail.2007.10.019. PMID:18325460.
7. Liu, T., Zhang, D.Y., Zhou, Y.H., Han, Q.F., Wang, L.H., Wu, L., and Yao, H.C. 2015. Increased serum HMGB1 level may predict the fatal outcomes in patients with chronic heart failure. Int. J. Cardiol. 184: 318–320. doi:10.1016/j.ijcard.2015.02.088. PMID:25746492.
8. Nguyen, A., Bhavsar, S., Riley, E., Caponetti, G., and Agrawal, D. 2016. Clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck cancer: a systematic review. Int. Arch. Otorhinolaryngol. 20(4): 382–389. doi:10.1055/s-0036-1583168. PMID:27746844.
9. Raposeiras-Roubín, S., Rodiño-Janeiro, B.K., Grigorian-Shamagian, L., Moure-González, M., Seoane-Blanco, A., Varela-Román, A., et al. 2010. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels. Eur. J. Heart Failure, 12(10): 1092–1100. doi:10.1093/eurjhf/hfq117. PMID:20685687.
10. Raposeiras-Roubín, S., Rodiño-Janeiro, B.K., Grigorian-Shamagian, L., Moure-González, M., Seoane-Blanco, A., Varela-Román, A., et al. 2011. Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score. Am. J. Cardiol. 107(6): 938–944. doi:10.1016/j.amjcard.2010.11.011. PMID:21247530.
11. Sims, G.P., Rowe, D.C., Rietdijk, S.T., Herbst, R., and Coyle, A.J. 2010. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28: 367–388. doi:10.1146/annurev.immunol.021908.132603. PMID:20192808.
12. Volz, H.C., Laohachewin, D., Schellberg, D., Wienbrandt, A.R., Nelles, M., Zugck, C., et al. 2012. HMGB1 is an independent predictor of death and heart transplantation in heart failure. Clin. Res. Cardiol. 101(6): 427–435. doi:10.1007/s00392-011-0409-x. PMID:22231645.
13. Wang, L.J., Lu, L., Zhang, F.R., Chen, Q.J., De Caterina, R., and Shen, W.F. 2011. Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and nondiabetic patients with heart failure. Eur. J. Heart Failure, 13(4): 440–449. doi:10.1093/eurjhf/hfq231. PMID:21266376.
14. Willemsen, S., Hartog, J.W.L., van Veldhuisen, D.J., van der Meer, P., Roze, J.F., Jaarsma, T., et al. 2012. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. Am. Heart J. 164(5): 742–749.e3. doi:10.1016/j.ahj.2012.07.027. PMID:23137505.
15. Zile, M.R., Desantis, S.M., Baicu, C.F., Stroud, R.E., Thompson, S.B., McClure, C.D., et al. 2011. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ.: Heart Failure, 4(3): 246–256. doi:10.1161/CIRCHEARTFAILURE.110.958199. PMID:21350055.